WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentCHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias
Afficher le documentCYCLOOXYGENASE-2 INHIBITORS - Plans to review all medicines in this class
Afficher le documentETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis
Afficher le documentHERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada
Afficher le documentINFLUENZA VIRUS VACCINE - Interactions with drugs
Afficher le documentMEDROXY PROGESTERONE - Effect on bone mineral density
Afficher le documentPAMIDRONATE DISODIUM, ZOLEDRONIC ACID - Spontaneous reports of osteonecrosis of the jaw
Afficher le documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - ADRAC reviews use in children and adolescents
Afficher le documentTERBINAFINE - Reports of blood dyscrasias
Afficher le documentTRICYCLIC ANTIDEPRESSANTS - Overdose risk
Afficher le documentFEATURE
 

ETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis

Norway. The Norwegian Medicines Control Agency (NMCA) has issued a reminder that ethinylestradiol/ cyproterone (Diane) is associated with an increased risk of thrombosis. The NMCA has received 26 reports of adverse reactions associated with Diane, including 15 of venous thrombosis, two of which were fatal. They note that ethinylestradiol/ cyproterone (Diane) should be used with the same caution as oral contraceptives, and should not be used in women with known risk factors for thrombosis, such as smoking, obesity and a personal or family history of thrombosis.

Reference:

Nytt om Legemidler, 11 August 2004. Available on the Internet at www.legemiddelverket.no

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013